Outcomes After Biochemical or Clinical Progression in Patients With Multiple Myeloma

Opinion
Video

Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.

Emory v Vanderbilt _FaceOFF_OutcomesinPatientswithMultipleMyeloma
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      4 experts are featured in this series.
      Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
      4 experts are featured in this series.
      Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
      4 experts are featured in this series.
      Future Perspectives: What’s Next in NDMM?
      4 experts are featured in this series.
      Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
      4 experts are featured in this series.
      Jackson’s Journey with High Risk R/R MM
      4 experts are featured in this series.
      Role of Bridging Therapy for CAR-T Patients
      4 experts are featured in this series.
      Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
      4 experts are featured in this series.
      Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
      4 experts are featured in this series.
      Overview of Process of CAR-T Therapy
      Related Content
      Developers designed cemsidomide as an orally bioavailable small molecule degrader that targets IKZF1/3, which drive multiple myeloma and non-Hodgkin lymphoma.

      Cemsidomide Combo May Produce Responses in Multiple Myeloma

      Russ Conroy
      May 8th 2025
      Article

      Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      "[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.

      Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma

      Russ Conroy
      May 3rd 2025
      Article

      Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      “These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.

      Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

      Russ Conroy
      April 28th 2025
      Article

      Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.

      Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

      Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

      Roman Fabbricatore
      April 27th 2025
      Article

      Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.